Glyphic Biotechnologies
Glyphic Biotechnologies is a Berkeley, California proteomics company founded in 2021 that is developing ProSE (Protein Sequencing by Expansion) — a de novo, high-throughput, single-molecule protein sequencing technology designed to discriminate all 20 amino acids and their post-translational modifications. The company aims to make massively parallel proteome sequencing broadly accessible for drug discovery and biological research, and is backed by Wing Venture Capital. Glyphic currently publishes no public developer API, SDKs, or documentation surface; this profile captures its identity and domain-security posture in the API Evangelist network.
Glyphic Biotechnologies is profiled on the APIs.io network. Tagged areas include Company, Proteomics, Protein Sequencing, Biotechnology, and Life Sciences.
Glyphic Biotechnologies’ developer surface includes support and 8 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Operate 2
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 3
The organization behind the API
Other 1
Properties that don't map to a standard resource type